Introduction
Prion diseases are a family of progressive, fatal neurodegenerative disorders caused by the accumulation of the alternatively folded prion protein PrP Sc . In the CNS, prions produce neuronal cell death, spongiform vacuolation and gliosis. 1 The PrP Sc protein is extractable from diseased tissue and biochemically distinguished from endogenous PrP C by partial protease resistance and detergent insolubility. 2 Both PrP C and PrP Sc share the same amino acid sequence, but PrP Sc adopts an abnormal conformation that is transmissible and serves as a template for the conversion of host PrP C into the pathogenic prion isoform. 3, 4 The mechanism responsible for the transmission, conformational conversion of PrP C to PrP Sc and subsequent disease progression remains enigmatic.
Detection of infectious prions relies on combined use of immunoassay and histopathological assessment of brain tissue
Prion diseases are fatal neurodegenerative disorders caused by prion proteins (PrP). Infectious prions accumulate in brain through a template-mediated conformational conversion of endogenous PrP c into alternately folded PrP sc . Immunoassays toward pre-clinical detection of infectious PrP sc have been confounded by low-level prion accumulation in non-neuronal tissue and the lack of PrP sc selective antibodies. We report a method to purify infectious PrP sc from biological tissues for use as an immunogen and sample enrichment for increased immunoassay sensitivity. significant prion enrichment is accomplished by sucrose gradient centrifugation of infected tissue and isolation with detergent resistant membranes from lipid rafts (DRMs). At equivalent protein concentration a 50-fold increase in detectable PrP sc was observed in DRM fractions relative to crude brain by direct eLIsA. sequential purification steps result in increased specific infectivity (DRM >20-fold and purified DRM immunogen >40-fold) relative to 1% crude brain homogenate. Purification of PrP sc from DRM was accomplished using phosphotungstic acid protein precipitation after proteinase-K (PK) digestion followed by size exclusion chromatography to separate PK and residual protein fragments from larger prion aggregates. Immunization with purified PrP sc antigen was performed using wild-type (wt) and Prnp 0/0 mice, both on Balb/cJ background. A robust immune response against PrP sc was observed in all inoculated Prnp 0/0 mice resulting in antisera containing high-titer antibodies against prion protein. Antisera from these mice recognized both PrP c and PrP sc , while binding to other brainderived protein was not observed. In contrast, the PrP sc inoculum was non-immunogenic in wt mice and antisera showed no reactivity with PrP or any other protein.
requires limited digestion with proteinase-K (PK) to hydrolyze PK-sensitive PrP C while retaining the PK-resistant PrP Sc (PrP 27-30). The PrP 27-30 protein is smaller than PrP C and intact PrP Sc and thus can be recognized by a mobility shift following SDS-PAGE and Western blot detection with anti-PrP antibodies. 6, 7 This methodology is effective for the identification of PrP Sc from prion enriched samples such as brain. Yet prion accumulation in the brain is progressive and infected asymptomatic animals pose significant sampling challenges. Indeed, there appears to be minimal shedding or accumulation of PrP Sc in other more accessible tissue or fluid compartments. 8, 9 Moreover, variability in the efficacy of prion proteolysis of samples confounds detection of low-level PrP Sc . 10 Definitive assessment of prion infected Fig. 2A; t-test p < 0.001). Prion enrichment in DRM was further evaluated by Western blot with a detectable increase in band intensity for all three PrP Sc glycoforms in DRM fractions relative to crude brain homogenates (Fig. 2B) . PTA precipitation of DRM fractions resulted in increased prion detection relative to the DRM fraction alone. Figure 3 compares the oligomeric status of the PrP found in normal and scrapie enriched DRM preparations from brain homogenates. The DRM fractions were subjected to sedimentation gradient centrifugation in a linear sucrose gradient. Each gradient was then fractionated into 12 equal fractions and each fraction evaluated by Western blot probing with anti-PrP antibody ( Fig. 3 ; top part), anti-Caveolin-1 antibody ( Fig. 3 ; middle part) and anti-Flotillin-1 antibody ( Fig. 3 ; bottom part). PrP C in the DRM from normal brain resides as monomeric to high molecular weight aggregate with the detection of mono-and di-glycosylated isoforms predominant ( Fig. 3 ; top left part). In contrast, the PrP Sc in the DRM from diseased brain was observed as high molecular weight aggregate >400 kDa dominated by the mono-and di-glycosylated isoforms ( Fig. 3 ; top right part). Moreover, non-glycosylated PrP was readily detectable across the gradient at varied molecular weights in DRMs from prion infected brain, yet this isoform was PK-sensitive ( Fig. 3 ; bottom right part) suggesting detection of PrP C . Caveolin-1 and Flotillin-1, established lipid raft proteins, 18 were used as markers to validate the integrity of the gradients and were detected as high molecular weight oligomers ( Fig. 3 ; bottom left parts).
Limited PK-digestion of PrP Sc positive DRM fractions resulted in the proteolytic degradation of PrP C and the N-terminal truncation of PrP Sc to form PrP 27-30. Importantly, the PK-digested samples also included peptide fragments, PK and lipids. To isolate PrP
Sc from these contaminants, we exploited preferential binding and precipitation of PrP Sc by PTA. Following PK-digestion of PrP Sc DRM fraction, proteins were PTA precipitated then solubilized and fractionated over Sephadex G100. A major protein peak emerged at the column void fraction #5 (void >100 kDa; Figure  4A ; top part; solid line) where PrP Sc was detected by ELISA ( Fig.  4A ; top part; dashed line). Evaluation of eluted G100 fractions by western blot shows that the majority of PrP Sc was detected in the void fraction #5 (Fig. 4B) . Figure 4C shows that PrP Sc was further concentrated by a second PTA precipitation after elution from G100 (Fig. 4C) . Electrophoresis of the PTA concentrated G100 eluted fraction #5 followed by silver ( Fig. 4D ; left part) and Coomassie blue staining ( Fig. 4D ; middle part) revealed proteins at the correct molecular mass corresponding to PrP Sc detected by western blot ( Fig. 4D; right part) .
Using the hamster bioassay we showed that the DRM fraction (PrP Sc DRM) isolated from prion-infected brain animals is determined in post-mortem evaluation of brain tissue by immunoassay and histopathology from clinically symptomatic animals.
There remains an acute need for a sensitive and selective prion immunodiagnostic assay capable of pre-clinical assessment of infected animals from accessible tissues or fluids. 11 Most immunoassay detection limits are insufficient to detect low-level prion contamination that can transmit disease by bioassay. Current assays are confounded by reliance on removal of PK-sensitive PrP C as no antibody has emerged that can selectively distinguish infectious PrP
Sc from PrP C . 12 The need to remove PrP C protein from samples often diminishes immunoassay sensitivity by reducing the amount of PrP Sc and increasing assay background. Moreover, the occurrence of PK-sensitive PrP Sc isoforms poses additional concerns for many immunodiagnostic assays. 13 The difficulty of prion antibody generation is underscored by the identical primary structure of normal and abnormal PrP protein isoforms and isolation of purified infectious prion. The use of synthetic PrP peptides or recombinant PrP C has been successful in generating anti-PrP antibodies for detection of both PrP C and PrP Sc proteins. 14, 15 However, PrP C antigen has proven to be a poor immunogen as endogenous PrP C protein negates a robust immune response. 16, 17 The immunogenicity of PrP C antigen has been improved by using Prnp 0/0 mice with resulting production of high-affinity anti-PrP antibodies.
14 However, the use of a PrP C antigen invariably leads to production of antibodies that recognize PrP C with a low probability of generating a PrP Sc selective antibody. Here we report a simple methodology for the enrichment and purification of infectious PrP Sc antigen from brain for immunization of Prnp 0/0 / Balb/cJ mice. We show that purified PrP Sc antigen elicits a robust immune response in Prnp 0/0 , but not wt Balb/cJ, mice resulting in the production of antisera with significant anti-PrP activity. Notably, no antibodies were generated against other brain proteins confirming the relative purity and utility of the PrP Sc antigen preparation.
Results
A sucrose density gradient effectively separates soluble proteins from those that are detergent resistant at 4°C by exploiting differences in buoyancy properties due to lipid-association of some proteins. A measure of total protein following fractionation of crude brain homogenate (12 x 1 mL) showed that the majority of proteins (>99%) were retained at the bottom of the sucrose gradient between fractions #8-12 (40% sucrose), whereas a small protein peak (<1%) migrated to the zone of the 5/30% sucrose in fractions #4-5 corresponding to detergent resistant membrane (DRM) derived from lipid rafts (Fig. 1A) . Western blots of the gradient fractions from normal and diseased hamster brain reveal that most of the PrP C ( Fig. 1B ; top left part) and PrP Sc ( Fig. 1B ; top right part) were found in the DRM fraction #4 of the minor protein peak. As a positive control for DRM proteins, Flotillin-1, a known lipid raft protein, was detected by Western blotting from the same gradient fractions and localized as expected to DRM fraction #4 ( Fig. 1B ; bottom parts). Aliquots of each gradient fraction were used as antigen in a direct binding ELISA DRM-PK-PTA-G100) relative to 1% crude brain homogenate, respectively (Fig. 5B) .
Prnp 0/0 /Balb/cJ mice were immunized with a PrP Sc fraction enriched for prion infectivity according to the purification scheme outlined in Figure 6 . Antisera from PrP Sc immunized Prnp 0/0 /Balb/cJ mice (#1-2) bound recombinant Syrian hamster (recSHa) PrP(90-231) at an end-point dilution >1:30,000 by homogenate remained infectious (Fig. 5A) . Likewise, the purified PK-resistant PrP Sc from DRM fractions that had been PTA precipitated and fractionated over Sephadex G100 (PrP Sc DRM-PK-PTA-G100) retained infectivity (Fig. 5A ). Our purification scheme resulted in a progressive increase in both the ID50 and a >20-fold and >40-fold increase in specific infectivity of DRM fractions and purified DRM (PrP normal (PrP C ) and disease (PrP Sc ) hamster brain with (+) and without (-) PK-digestion is shown from a representative immunized Prnp 0/0 /Balb/cJ mouse by Western blot ( Fig. 8 ; top part). Weak binding to PrP C was observed in normal brain homogenate (30 µg/lane) compared to the strong binding to PrP C from enriched DRM (10 µg/lane) preparation (Fig. 8, PrP C ; arrow). Limited PK-digestion of normal brain samples resulted in the complete loss of detectable PrP C using the antisera. Strong binding to PrP Sc was observed in both crude brain homogenates and DRM preparations from disease brain with detection of PrP 27-30 at the expected molecular mass. Importantly, antisera from immunized Prnp 0/0 /Balb/cJ mice only detected PrP proteins. As a control, a companion blot was probed with the antiPrP monoclonal antibody IPC1 ( Fig. 8; bottom part) . A similar pattern of binding to PrP C and PrP Sc was observed with IPC1 as compared to the antisera from immunized Prnp 0/0 /Balb/cJ mice. To determine if antisera from prion immunized mice binds to non-denatured prion proteins we performed ELISA on hamster brain DRM fractions (Fig. 9) . Our data shows that the antisera was equally effective in the detection of the native prion protein from both normal (PrP C ) and diseased (PrP Sc ) DRM fractions. However, following PK treatment the antisera bound only PK-resistant PrP27-30 from diseased brain (PrP Sc ) with binding levels equivalent to background in PK-treated normal brain (PrP C ). Thus sera from mice immunized with the purified prion preparation have antibodies that recognized both the normal (PrP C ) and abnormal (PrP Sc ) prion isoforms. Importantly, there was no detection of other brain proteins which supports the validity of this strategy for use with hybridoma technology to isolate sensitive and selective anti-prion monoclonal antibodies.
Discussion
The most common methods for the diagnostic confirmation of prion disease involve clinical assessment, followed by postmortem histopathological evaluation of brain tissue along with biochemical detection of PrP 27-30. 19, 20 Several problems have confounded the pre-clinical diagnostic detection of prion. First, accumulation of PrP Sc increases progressively over time; second, most PrP Sc resides in the brain which imposes biopsy challenges. Third, prion concentrations below current immunoassay detection limits can transmit disease in animal bioassay. 21, 22 Fourth, no direct detection method has been developed that can distinguish PrP
Sc from PrP C without enzymatic or chemical manipulation to render endogenous PrP C undetectable while retaining PrP Sc activity. Indeed, no antibody has emerged that can selectively bind PrP Sc . Moreover, no surrogate analyte has been identified that can identify prion disease in preclinical animals. 23, 20 Finally, species and prion strain variability presents additional detection challenges as a result of distinct tissue distribution and availability. 24, 25 Useful biochemical methods have emerged for the enrichment of PrP Sc from brain homogenates that take advantage of differences in sedimentation and solubility. 26, 27 Yet, these preparative methods have proven insufficient to yield PrP Sc enriched fractions suitable for crystal formation or as immunogen for the generation ELISA (Fig. 7A) . No SHa PrP(90-231) binding was observed using sera from immunized wt Balb/cJ mice (#3-4). Western slot-blot experiments compared binding of antisera from immunized Prnp 0/0 /Balb/cJ mice #1-2 and wt Balb/cJ mice #3-4 ( Fig.  7B) to recSHaPrP(90-231), SHaPrP Sc DRM without limited PK-digestion (PrP C plus PrP Sc ) and SHaPrP 27-30 in DRMs. Antisera from immunized Prnp 0/0 /Balb/cJ mice was effective in detecting both PrP C and PrP Sc proteins at dilutions >25 K. In contrast, antisera from immunized wt Balb/cJ mice did not detect PrP proteins at any dilution tested. The lack of immunoreactive sera from immunized wt Balb/cJ mice to other DRM proteins further supports the purity of the prion inoculum and lack of immunogenicity of the PrP Sc protein in wt animals. Further characterization of antisera binding to protein in crude brain homogenate and brain-derived DRM fractions from Sc truncation to form PrP 27-30. Phosphotungstic acid (PTA) has been used effectively to precipitate prion protein. 35, 36 The application of PTA to precipitate PrP Sc after PK-digestion from DRMs provides an effective method to both concentrate and separate prion from lipids in the enriched DRM preparation. In addition, we found PrP Sc in brain DRM fractions is highly aggregated with a molecular mass of >400 kDa. We exploited this property by using size exclusion chromatography to further separate PrP Sc from residual PK (<30 kDa) and other protein fragments. Chromatography over Sephadex G100 allowed us to rapidly collect the majority of PrP Sc in the column void fraction while residual proteins <100 kDa were retarded by the gel. The resulting PrP Sc fraction (PrP Sc DRM-PK-PTA-G100) retained infectivity as determined in bioassay. The PrP Sc fractions from multiple column separations were pooled and concentrated by a second PTA precipitation to yield a highly purified PrP Sc pellet (PrP Sc DRM-PK-PTA-G100-PTA). This method (outlined in Fig. 6 28 Third, the method used for screening antibodies requires the selective discrimination of those that bind PrP C from those that bind PrP Sc . Here we report the development of prion purification methodology that yields abundant PrP Sc from diseased brain (Fig. 6) and demonstrate a progressive increase in specific infectivity of prions in DRMs (>20-fold) and the purified DRM-PK-PTA-G100 (>40-fold) inoculum relative to a 1% crude brain homogenate. Moreover, we show that purified PrP Sc is highly immunogenic in Prnp 0/0 /Balb/cJ, but not wt Balb/cJ, mice resulting in generation of high-titer antisera with selective activity to PrP.
Post-translational processing of PrP C includes the addition of a GPI-anchor that targets the protein to lipid rafts of the plasma membrane. 29, 30 This localization is important for the conformational conversion of PrP C into infectious prion. [31] [32] [33] [34] Biochemically these lipid-rich membrane domains can be isolated by sucrose density centrifugation as buoyant detergent resistant membranes (DRMs) containing both PrP C and PrP Sc proteins. 29, 10 Exploitation of this methodology allows for a significant enrichment and purification, effectively separating >99% of brain protein from prion in a single step. The resulting DRM fraction is in wt animals or production of antibodies that crossreact with PrP C . The structural distinction of PrP Sc by the immune system likely represents a statistically rare event. Such an interpretation is supported by its failure to recognize PrP Sc as foreign following immunization of wt mice with the purified PrP Sc . The development of a Prnp 0/0 /Balbc/J mouse provides a useful genetic background to promote a robust immune response to prions and production of monoclonal antibodies. These mice offer a syngenic background for myeloma-spleenocyte fusion and subsequent hybridoma generation. Indeed, our data shows that despite the purity of our prion inoculum it serves as a poor immunogen in wt Balb/cJ mice. However, the lack of detection of any other brain DRM proteins using the antisera from immunized wt Balbc/J mice supports the purity of our prion inoculum. In sharp contrast, immunization of Prnp 0/0 /Balb/cJ mice elicits a robust immune response that resulted in production of high-titer antiprion specific antiserum. The response appears comparable by Western blot to that observed with established monoclonal anti-PrP antibodies. Additionally, no antibodies against other brain DRM proteins were detected in the antisera from these mice again suggesting a highly purified inoculum.
Antisera from the Prnp 0/0 /Balb/cJ mice recognized both PK-sensitive and -resistant PrP proteins. This is not surprising given the identical primary amino acid sequence of PrP Sc to PrP C and it suggests that a pool of antibodies were produced against multiple epitopes resulting in cross-reactivity with sera by immunoassay. However, the model outlined here is well suited for the generation of hybridomas and isolation of monoclonal antibodies. Efforts are underway to isolate monoclonal antibodies and identify those that bind PrP Sc specific epitopes. In conclusion, we have developed a method for the enrichment of infectious prions from lipid rafts and their subsequent purification in sufficient quantity to elicit a robust and selective immune response in Prnp 0/0 /Balb/ cJ mice. immunizaton with purified prion still presents additional challenges to the immune system to generate a PrP Sc selective antibody. There remains a need for the immune system to present a structurally unique PrP Sc target in order to generate a selective antibody capable of distinguishing PrP
Sc from PrP C . Indeed antigen processing of prion by the immune system may likely results in a majority of the prion fragments being recognized as "self" thus provoking a minimal (or no) immune response Figure 4 . concentration and purification of prion by PTA and size exclusion chromatography. enriched PrP sc DRM fractions were treated with proteinase-K then proteins PTA precipitated, the solubalized (PrP sc DRM-PK-PTA) material was then fractionated by size exclusion chromatography (sephadex G100). Protein concentration of fractions was determined by BcA assay (A; solid line) and PrP sc detection by eLIsA (A; dashed line). A small protein peak was observe in fraction #5 that corresponded to the void fraction of the column (proteins >100 kDa) which also contained the majority of detectable PrP sc . Western blot detection of G100 fractionated PrPsc DRM-PK-PTA-G100 showed a major band in the void fraction #5 (B). A second PTA protein precipitation following G100 fractionation recovered detectable PrP sc in the void fractions (c). evaluation of the purified PrP sc DRM-PK-PTA-G100-PTA material by silver and coomassie stain (D; left and middle part respectively) showed detectable PrP sc protein at the expected molecular weight that corresponded to PrP formed by applying 4 mL of the 40% brain-sucrose in the bottom of a clear ultra-centrifuge tube (14 x 89 mm; Beckman, CA) followed by a 4 mL layer of 30% MES-Sucrose then 4 mL 5% MES-Sucrose. Tubes were placed in a SW-40T rotor and centrifuged at 39,000 RPM at 4°C for 18 h in a L8-70M class H ultracentrifuge (Beckman). A visible lipid-rich band corresponding to the detergent resistant membrane (DRM) fraction was observed within the 30-5% sucrose zone and collected (∼1 mL/gradient).
DRM fractions obtained from hamster brain homogenates were mixed with n-octyl-glucoside to a final concentration of 60 mM and incubated at 4°C for 15 min with rotation. A cushion of 250 µL of 50% sucrose in 25 mM MES (pH 6.5) with 150 mM NaCL and 60 mM n-octyl-glucoside was place in the bottom a clear ultra-centrifuge tubes (11 x 60 mm; Beckman) and a 50-5% linear sucrose gradient (4 mL) formed using a mixing gradient maker. The DRM fraction was loaded (300 µL) to the top of the gradient and tubes centrifuged in a SW60 rotor at 50,000 RPM for 10 h at 4°C in a L8-70M class H ultra-centrifuge. 12 x 0.35 mL fractions were collected and analyzed. The gradient was calibrated with known molecular standards as previously described.
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Material and Methods
All animals were housed in pairs on a 12 h light-dark cycle and provided continual access to food and water. All protocols were approved by the USDA animal care and use committee and experimental procedures conducted in certified BL2 laboratory. Hamster-passaged Sc237 scrapie prions were propagated in female Syrian Golden hamsters (LVG; Charles Rivers Laboratory, MA) beginning at 4 weeks of age. Prion-infected hamsters were sacrificed when clinical symptoms included; increased startle response, ataxia and >5 s righting reflex. Prnp 0/0 /Balb/cJ mice were generated at the University of California, San Francisco under approved animal protocols by speed congenic backcrossing 129/SvJ/C57-BL6 Prnp 0/0 to inbred Balb/cJ mice and homozygosity verified by PCR as previously described. 37, 14 Antisera was obtained from anesthetized mice following transcardiac puncture with a 20-gauge needle attached to a 3 mL syringe, transferred to a BD Vacutainer SST tube (BD Biosciences), allowed to clot and sera collected after centrifugation.
Infectious PrP Sc was propagated by serial passage in hamster brain following 40 µL intracerebral inoculation of a 1% brain homogenate in 320 mM sucrose using a 27-gauge needle inserted into the right parietal lobe. Detergent resistant membrane (DRM) fractions were diluted in sucrose to a final concentration of 320 mM and inoculated as described. Phosphotungstic acid (PTA) precipitated protein pellets were solubalized in n-octyl-glucoside to final concentration of 60 mM, diluted in sucrose and inoculated as described. Incubation time assay was used to calculate ID50 using the equation Log T = 17 + [Log D] -(0.138*Y) and used for calculation of specific infectivity (ID50/ mg inoculum). Onset of clinical scrapie was determined by occurrence of two symptoms in days post-inoculation as defined above. Prnp 0/0 /Balb/cJ mice starting at 25 d were inoculated (i.p.) with 100 µL antigen using the following regime: two inoculations containing purified PrP Sc in RIBI adjuvant (Sigma-Aldrich, MO; Sigma Adjuvant System) separated by 10 days. Sera was collected 3 days after the final inoculation and evaluated for antiPrP immunoreactivity.
All reagents were of the highest grades commercially available. All antibodies were diluted in 10 mM Tris Buffered Saline with 1% Tween-20 (TBST) containing 1% IgG-free BSA (Jackson Immuno Chemical, PA). Primary antibodies used include: Caveolin-1 rabbit polyclonal diluted 1:1 K (Santa Cruz, CA; N20), Flotillin-1 rabbit polyclonal diluted 1:1 K (Santa Cruz; H-104), IPC1 anti-prion monoclonal diluted 1:10 K (Sigma). Secondary antibodies include: goat-anti-mouse-HRP and goat-anti-rabbit-HRP diluted 1:10 K (Pierce, IL). Recombinant Syrian hamster (recSHa) PrP(90-231) was generated at UCSF as previously described. 38 Hamster brains were homogenized (10% w/v) on ice in 25 mM MES (pH 6.5) with 150 mM NaCL, 1% Triton X-100, 60 mM n-octyl-glucoside, 10 mM PMSF and protease inhibitors (Complete mini; Roche, CH). The homogenate was pre-cleared by centrifugation (1,000x g) at 4°C and supernatant mixed with equal volume of 80% sucrose in 25 mM MES (pH 6.5) with 150 mM NaCL. A 12 mL discontinuous sucrose gradient was µg) and PrP sc PK-treated PTA precipitated material fractionated by size exclusion on sephadex G100 (PrP sc DRM-PK-PTA-G100; 0.8 µg). N = sample size. comparison of ID50 and specific infectivity following intracerebral inoculation of 1% crude brain homogenate (brain), DRM and purified prion (DRM-PK-PTA-G100) by incubation time assay (B). Isolation of PrP sc in DRMs from lipid rafts results in >20-fold and purified PrP sc DRM-PK-PTA-G100 >40-fold, increase in specific infectivity relative to crude brain.
Protein concentration was quantified using a micro-BCA assay (Pierce). Proteinase-K (PK; Roche) treatment was used at a final concentration of 25 µg/mL for brain homogenates and 150 µg/mL for DRM fractions for 1 h at 60°C and inactivation of PK was by denaturation in LDS sample buffer or by addition of PMSF to 10 mM. Electrophoresis was performed on heat denatured samples in LDS buffer normalized by BCA and loaded on 4-12% Bis-Tris gels electrophoresed with MOPS running buffer (Novex; Invitrogen). Gels were transferred to nitrocellulose (Bio-Rad), washed in TBST, blocked with 10% non-fat dry milk, probed with antibodies, protein bands resolved by ECL (Supersignal; Pierce) and imaged on a Flurochem HD documentation system (Alpha Innotech, CA). Gel staining was performed with Coomassie blue (R250; Sigma) or Silver (ProteoSilver Plus; Sigma) and imaged on a light box.
Samples with equivalent protein concentration were diluted in 0.1 M sodium bicarbonate buffer (pH 9.4) and 100 µL absorbed to 96-well maxisorb plates (NUNC, NY) overnight at 4°C. Plates were washed in TBST, blocked in 10% non-fat milk for 1 h at 37°C, incubated 1 h with primary antibody, washed, incubated 1 h with HRP-conjugated secondary antibody, washed, resolved by chemiluminescence (Supersignal; Pierce) detection using Victor2 plate reader (PerkinElmer, MA) and expressed as relative light units (RLU).
A stock of sodium phosphotungstate hydrate (Aldrich, WI) was dissolved at 4% in PBS (pH 7.4) with 170 mM MgCl2. PTA was added to samples to a final concentration of 0.3% with 13 mM MgCL2 and incubated at room temperature for 10 min. Precipitated protein was centrifuged at 10,000x g for 20 min at 4°C, pellets washed repeatedly with 200 mM EDTA in PBS followed by centrifugation with a final wash in ddH20 with remaining water aspirated after centrifugation. PTA pellets were solubalized with n-octylglucoside to a final concentration of 60 mM in buffer.
A 15 mL gel bed of Sephadex G100 (Superfine grade, Sigma) was poured in a glass column and equilibrated in 25 mM Tris-HCL (pH 7.4). Column calibration was performed with gel filtration standards (Bio-Rad, CA; #151-1901) and samples loaded at 250 µL in 25 mM Tris-HCL (pH 7.4) with 60 mM n-octyl-glucoside. Proteins were fractionated with 25 mM Tris-HCL (pH 7.4) at a flow rate of 100 µL/min in 1 mL fractions. Column void was defined at 5 mL with detectable high molecular weight standards (>100 kDa) eluted. 
